New positive data on lefitolimod in HIV
About TEACHTEACH (Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV infection) is a non-randomized interventional phase I/IIa trial to evaluate lefitolimod (MGN1703) in HIV positive patients. Thus, lefitolimod (MGN1703) could play a role in the "kick and kill" concept of HIV eradication. HIV infects the immune system and destroys or affects the proper function of immune cells. In addition, the data suggest that a similar tumor microenvironment development can be expected in the IMPALA study, a pivotal study of lefitolimod in metastatic colorectal cancer. The TEACH study started in June 2015 and has since been extended based on the broad immune system activation induced by lefitolimod.
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
These patients were randomised to either stay on their three- or four-drug regimen or switch to a dolutegravir and rilpivirine regimen. These data mark an exciting first step towards making two drug regimens a reality in HIV treatment. The overall rate of serious adverse events was comparable between treatment groups (dolutegravir + rilpivirine: 27, CAR: 21). Use of dolutegravir and rilpivirine as a two-drug regimen for HIV-1 maintenance therapy is investigational and not approved anywhere in the world. Your healthcare professional will measure your viral loadEDURANT® should be taken in combination with other HIV medicines.collected by :Lucy William
To follow all the new news about
No comments:
Post a Comment